Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."
Wall Street is fed up with Trump’s tariffs. Stocks are off to their worst start to a year since 2022
As Wall Street heads into a new quarter, a flurry of President Donald Trump’s tariffs are set to go into effect. That has traders on edge and has helped put US stocks in their worst first-quarter slump in years.
‘Frustration and Fatigue’ Hit Stock Traders in Run-Up to Tariffs
(Bloomberg) -- The Trump administration’s mixed messaging on what new tariffs will be unveiled Wednesday and how they’ll be announced have equities traders flustered as they try to position around the biggest risk confronting the market in years.Most Read from BloombergWhat Frank Lloyd Wright Learned From the DesertGold-Rush Fever Returns to Historic New Zealand Mining TownBank Regulators Fight for Desks as OCC Returns to New York Tower“The best way to summarize this trading environment is frust
Trump is knowingly steering the economy off the cliff with tariffs
The problem is not tariffs—the problem is Donald Trump.
Tariffs Are Hitting The U.S. Economy Where It Hurts
President Donald Trump's tariffs are already shifting how people spend their money, an ominous sign for the future of the economy.
Bitcoin Headed Below $60K Says Hot-Handed Crypto Hedge Fund Manager
D.O.G.E. job cuts, tariffs, a restrictive Fed and new immigration policies could weigh on markets for the next six to nine months, said Lekker Capital's Quinn Thompson.
Why Is Corcept (CORT) Stock Soaring Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Innovation Amid Yield Compression: DeFi Lending Markets in Q1 2025
While yields across major lending platforms have compressed significantly, innovation at the market's edges demonstrates DeFi's continued maturation and growth, says Ryan Rodenbaugh, CEO of Wallfacer Labs, the team behind vaults.fyi.
Newsmax Stock Surges in NYSE Trading Debut
Shares of conservative news outlet Newsmax skyrocketed in the company’s first day of trading on the New York Stock Exchange Monday after a $75 million initial public offering.
Canada Goose Stock Sinks to All-Time Low on Barclays Downgrade
Shares of Canada Goose Holdings set a new record low Monday after analysts from Barclays downgraded the apparel maker's stock.